Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
View original at finance.yahoo.comJanux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 -JANX014 expands Janux’s PSMA tumor-activated T cell engager portfolio -JANX007 is the Company’s lead prostate cancer program and primary development priority -JANX013, a PSMA-TRACIr CD28 co-stimulatory program, planned to enter the clinic…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
JANX007 has shown a favorable safety profile with no Grade 3 cytokine release syndrome observed at clinically relevant dose levels using the current CRS mitigation strategy
60% confidenceWe are building a prostate cancer portfolio designed to address patients across multiple stages of disease, including both single and combination approaches
60% confidenceJANX007 remains our lead prostate program, and we believe it has established a strong clinical foundation for PSMA-directed TRACTr therapy
60% confidenceJanux's tumor-activated technology allows us to evaluate multiple molecular designs against the same validated target
60% confidenceEarly clinical data from JANX007 have demonstrated what Janux believes is potentially a best-in-class clinical profile in mCRPC
60% confidence